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Abstract
For several years, the first line of treatment of glioblastoma (GB) patients is
based on surgical resection followed by fractioned radiotherapy with concomitant
and adjuvant chemotherapy with temozolomide (TMZ). The effectiveness of
this treatment is very limited due to the development by tumor cells of
mechanisms of resistance to TMZ such as over-expression of O6-methylguanine
DNA methyltransferase (MGMT), epidermal growth factor receptor (EGFR) and
galectin-1. In this study, we hypothesized that the targeting of MGMT, EGFR and
galectin-1 (alone or in combination) by specifics siRNAs carried by chitosan-lipid
nanocapsules (chitosan-LNCs) could enhance the sensitivity of U87MG cells to
TMZ. We showed in vitro that (i) anti-MGMT and (ii) anti-EGFR or anti-galectin-1
siRNAs decreased significantly the expression of their corresponding proteins
and increased the sensitivity of U87MG cells to TMZ. Additionally, the sensitivity
of U87MG/MGMT- cells to TMZ was significantly increased when ...
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Combined silencing expression of MGMT with 
EGFR or galectin-1 enhances the sensitivity of 
glioblastoma to temozolomide
Abstract: For several years, the first line of treatment of 
glioblastoma (GB) patients is based on surgical resection 
followed by fractioned radiotherapy with concomitant 
and adjuvant chemotherapy with temozolomide (TMZ). 
The effectiveness of this treatment is very limited due to 
the development by tumor cells of mechanisms of resist-
ance to TMZ such as over-expression of O6-methylgua-
nine DNA methyltransferase (MGMT), epidermal growth 
factor receptor (EGFR) and galectin-1. In this study, we 
hypothesized that the targeting of MGMT, EGFR and 
galectin-1 (alone or in combination) by specifics siRNAs 
carried by chitosan-lipid nanocapsules (chitosan-LNCs) 
could enhance the sensitivity of U87MG cells to TMZ. We 
showed in vitro that (i) anti-MGMT and (ii) anti-EGFR 
or anti-galectin-1 siRNAs decreased significantly the 
expression of their corresponding proteins and increased 
the sensitivity of U87MG cells to TMZ. Additionally, the 
sensitivity of U87MG/MGMT- cells to TMZ was signifi-
cantly increased when anti-EGFR and anti-galectin-1 siR-
NAs were  combined with a percentage of living cells of 
17.8±1.6% at 0.5 mg/mL concentration of TMZ. The com-
bination of anti-MGMT siRNAs with either anti-EGFR or 
anti-galectin-1 siRNAs enhanced the sensitivity of U87MG/
MGMT+ cells to TMZ in comparison to their separately 
use. No difference was observed between the association 
of the three siRNAs and other associations. At 0.5 mg/
mL concentration of TMZ, the percentage of living cells 
decreased from 55.1±1.9% to 36.0±4.1% for anti-MGMT 
alone and the combination of anti-MGMT/anti-galectin-1/
anti-EGFR siRNAs, respectively. These siRNA nanovectors 
represent a good alternative to enhance the effectiveness 
of the standard treatment of GB. This method could be 
implemented in future preclinical models for experimen-
tal cancer treatment of GB.
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Introduction
Glioblastoma (GB) is the most aggressive among brain 
tumors and the most resistant to current treatment com-
bining surgery, radiation, and chemotherapy by oral 
Temozolomide (TMZ) (1, 2). Median survival is 14 months 
and the percentage of patients living for 5 years or more 
is  < 10% (1, 3). TMZ is an alkylating agent from the imida-
zotetrazine family; it acts by methylation of purine bases 
of DNA (O6-guanine; N7-guanine and N3-adenine) (4). 
The cytotoxicity of TMZ is mainly mediated by the forma-
tion of O-6 methyl guanine responsible of mispairment 
with thymine during DNA replication; this causes toxic 
lesions of DNA and cell cycle arrest (5, 6).
The efficacy of TMZ for treating GB is very limited 
due to TMZ resistance. This is mainly due to high levels 
of enzyme activity of DNA repair O6-methylguanine DNA 
methyltransferase (MGMT) expressed in glioma cells (7). 
This enzyme acts by removing the methyl group from 
guanine and restores the DNA strand (8). On the other 
hand, overexpression of epidermal growth factor receptor 
(EGFR) and galectin-1 by tumor cells significantly contrib-
utes to TMZ resistance (3, 9). EGFR gene amplification is 
the most frequent genetic alteration in primary GBs with 
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a frequency of 40% (10), and approximately, half of these 
tumors carry the rearranged EGFR gene resulting in tumors 
expressing both wild-type EGFR as well as a mutated 
EGFR (11). EGFRvIII is the most common variant of EGFR 
in GB in which the extracellular domain of the receptor 
is lacking, resulting in constitutive activation (12). EGFR 
activates strongly Ras/Raf/MAPK (13) and PI3K/AKT/m-
TOR (14) signaling pathways that cause an inhibition of 
cell autophagy and apoptosis responsible of the decrease 
of TMZ efficiency (15). Galectin-1 belongs to lectin family 
containing a carbohydrate recognition domain (CRD) that 
confers to galectin-1 a high affinity for β-galactosides (3, 
16). It acts by stimulation of Ras/Raf/MAPK signaling 
pathway and by the inhibition of p53 transport to the 
nucleus that also contributes to TMZ resistance (17).
Given the involvement of MGMT, EGFR and galectin-1 
in the pathogenesis of GB, it seems very likely that reduc-
ing their cell expression and functionality will improve 
the sensitivity of GB to TMZ. Various strategies can be 
used to achieve this goal. Among them, small interfering 
RNAs (siRNAs) are very promising. They are small double-
stranded RNAs of 21–23 bp that reduce the expression of 
specific genes with complementary nucleotide sequences 
(18, 19). They operate by specific incorporation into RNA 
induced silencing complex (RISC) that becomes active. 
Following that, the antisense strand remains in the RISC 
complex and guides the RNA interference enzymatic 
machinery while the sense strand of the RISC complex is 
eliminated. Degradation of the complementary mRNA is 
provided by nuclease argonaute 2 (20, 21) and leads to a 
reduced protein expression.
Unfortunately, the use of therapeutic siRNAs alone 
(i.e., directly injected as naked molecule without any adju-
vant) is not possible for several reasons. Among these, (i) 
their negative charge that prevents them from crossing the 
plasma membrane to reach their target into the cytoplasm 
(20, 22), (ii) their degradation after their injection into 
the blood by nucleases present in plasma and cytoplasm 
(23), and (iii) the immune response that can be triggered 
by their presence in the blood (23). For these reasons the 
use of vectors that allow efficient siRNA delivery into the 
target cells is necessary.
Many non-viral vectors of siRNAs have been devel-
oped. They differ from each other by their composition 
and method of preparation (24, 25). Some of these vectors 
have been designed either to encapsulate siRNAs (26) or to 
attach them to their surface.
We chose to complex siRNAs to the surface of lipid 
nanocapsules (LNCs) because of their water-soluble 
nature and to allow them to be efficient without a need 
of release from the nanocapsule structure. Additionally, 
the oily core of these nanoparticles should allow us to 
consider the co-encapsulation of lipophilic anticancer 
drugs in the future. In this context, chitosan-transacylated 
lipid nanocapsules (chitosan-LNCs) have been previously 
developed for the transport of siRNAs (27). This cationic 
vector was obtained after grafting chitosan at the surface 
of LNCs produced by a phase inversion method (28). This 
process is green: no organic solvents are used. Moreover, 
only generally recognized as safe (GRAS) and genetically 
modified organisms (GMO) free excipients are used (29). 
The positive charge of chitosan allows for fixing the nega-
tively charged siRNAs to the vector surface by electrostatic 
attraction. Chitosan was selected as the transacylation 
polymer for its interesting physicochemical properties in 
particular its non-toxicity and biocompatibility (30).
In a previous study, we highlighted the interest to use 
anti-EGFR siRNA-chitosan LNCs to increase the sensitivity 
of GB cells to TMZ (27). Knowing that EGFR overexpression 
is not the only factor involved in the resistance of GB cells to 
TMZ, the aim of this work was (i) to produce and character-
ize siRNA-chitosan LNCs able to target several proteins that 
participate in TMZ resistance, in particular MGMT, EGFR 
and galectin-1, and (ii) to study the sensitivity of human GB 
cells to TMZ after siRNA treatment alone or in combination.
Materials and methods
Materials
Solutol® HS 15 (BASF, Ludwigshafen, Germany) is a mixture of free 
polyethylene glycol 660 (PEG) and polyethylene glycol 660 hydroxy-
stearate, Labrafac® WL 1349 (Gattefossé S.A., Saint-Priest, France) is a 
mixture of capric and caprylic acid triglycerides, NaCl was purchased 
from Prolabo (Fontenay-sous-Bois, France), Lipoïd® S75-3 (Lipoïd 
GmbH, Ludwigshafen, Germany) is a soybean lecithin made of 69% 
of phosphatidylcholine, 10% phosphatidylethanolamine and other 
phospholipids, Milli-Q water was obtained from a Milli-Q-plus® sys-
tem (Millipore, Paris, France). Chitosan oligosaccharide lactate 5 kDa 
with a degree of deacetylation  ≥ 75% was purchased from Sigma 
Aldrich (Saint-Quentin Fallavier, France). The dialysis membrane was 
purchased from Spectrum Laboratories (Rancho Dominguez, USA) 
and has a molecular weight cut-off point equal to 50 kDa. O-Phthalal-
dehyde (OPA) was purchased from Thermo Scientific (Rockford, USA). 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) was purchased from Sigma Aldrich (Saint-Louis, USA).
Methods
Cell line culture: Human GB U87MG/MGMT- cells were obtained 
from LGC (Molsheim, France). Human GB U87MG/MGMT+ cells were 
kindly provided by Professor Kaina Bernd (Mainz, Germany). These 
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cells were cultured in Dubelcco’s modified Eagle’s medium (DMEM) 
supplemented with 10% of fetal bovine serum (FBS) (Lonza, Ver-
viers, Belgium) and 1% of antibiotics (Sigma Aldrich, Saint-Louis, 
USA) at 5% CO2/37°C.
Formulation of siRNA/chitosan-LNCs complexes: As previously 
described (27), LNCs with a diameter of 50 nm were prepared accord-
ing to a phase-inversion process (28), and the chitosan grafting on 
their surface was obtained by a transacylation reaction. The final 
concentration of chitosan in nanoparticles formulation was 1.2 mg/
mL. Transacylated LNCs and siRNA were mixed in order to have a 
final concentration of chitosan-LNCs of 100 μg/mL and concentra-
tion of anti-EGFR and anti-galectin-1-siRNAs of 40 nM. The anti-
MGMT-siRNA concentration used was 5 nM. The siRNA sequences 
(Eurogentec, Angers, France) used are indicated in Table 1.
Characterization of siRNA/chitosan-LNCs complexes: The average 
hydrodynamic diameter, polydispersity index (PDI) and zeta potential 
of chitosan-LNCs and siRNA/chitosan-LNCs complexes were measured 
by DLS using NanoZS® (Malvern Instruments, Worcestershire, UK). 
Measurements were performed in RNAse free water in triplicate at 25°C 
with comparable conductivity values for zeta potential determination.
Stability of siRNA/chitosan-LNCs complexes: The stability of all 
siRNA/chitosan-LNCs complexes tested in this study was evaluated 
at 4 and 25°C in RNAse free water for 72 h. For this purpose, measure-
ments of hydrodynamic diameter, PDI and zeta potential were per-
formed using a NanoZS®.
siRNA transfection: U87MG/MGMT- or U87MG/MGMT+ were plated 
in 24-well plates at a density of 25 × 103 cells/well. After 48 h, the 
culture medium was removed and cells were treated with siRNA/
chitosan LNC complexes. The final concentration of chitosan-LNCs 
was 100 μg/mL. Anti-MGMT siRNA at the concentration of 5 nM was 
tested on U87MG/MGMT+ cells while anti-EGFR and anti-galectin-1 
siRNAs (40 nM) was tested on U87MG/MGMT- cells.
Moreover, combinations of these siRNAs were also evaluated: (i) 
the effect of the combination of anti-EGFR and anti-galectin-1 siRNAs, 
on U87MG/MGMT- cells; and (ii) the combinations of anti-MGMT/
anti-EGFR siRNAs, anti-MGMT/anti-galectin-1 siRNAs or anti-MGMT/
anti-EGFR/anti-galectin-1siRNAs, on U87MGMGMT+ cells. The nega-
tive control tested was a scramble siRNA carried by chitosan-LNCs 
(Eurogentec, Angers, France).
Flow cytometry: Four days after the siRNA transfection, cells were 
harvested from the bottom of the plate by the Versene® (EDTA) 0.02% 
(Lonza, Verviers, Belgium), re-suspended in PBS supplemented with 
5% FBS and 0.02% NaN3, and incubated on ice for 1 h with mouse 
anti-EGFR and anti-MGMT (BD Biosciences, Le Pont de Claix, France), 
and mouse anti-galectin-1 (R&D systems, Abingdon, UK) antibodies 
or isotype control antibodies.
For MGMT and galectin-1, cells were permeabilized with the BD 
cytofix/cytopermTM fixation/permeabilization kit (BD Biosciences) 
before addition of primary antibodies. Following incubation, cells 
were washed and further stained with fluorescein isothiocyanate 
(FITC)-conjugated goat F(ab′)2 anti-mouse immunoglobulin (Dako, 
Trappes, France) or anti-goat immunoglobulin (R&D systems) for 
30 min on ice. Cells were then washed and fixed in 2% formaldehyde. 
The stained cells were analyzed in a FACScan flow cytometer with 
CellQuest Software (BD Biosciences, San Jose, CA, USA). Specific 
expression of the protein was defined as the ratio of the geometric 
mean of the respective antibody to the geometric mean of the isotype 
and further normalised to treatment versus control condition.
Survival assay: As aforementioned, U87MG/MGMT- or U87MG/
MGMT+ cells were plated for 48 h in 24-well plates and then treated 
for 72  h with siRNA/chitosan-LNCs complexes (siRNAs concentra-
tions: 5 nM for anti-MGMT and 40 nM for anti-EGFR and anti-galec-
tin-1 siRNAs).
At the end of the incubation period, the culture medium from 
each well was changed and cells were treated with or without TMZ. 
Two concentrations of TMZ were tested: 0.03 and 0.50 mg/mL. After 
24 h, the culture medium was changed in each well and a volume 
of 40 μL of the MTT reagent was added and incubated for 4 h in the 
dark at 37°C. The supernatant was then aspirated and a volume of 
400 μL of acidic isopropanol was added to each well to dissolve the 
previously-obtained formazan crystals. The plate was left under 
mechanical stirring and the contents of each well was transferred to a 
96-well plate to perform the reading Multiskan Ascent ® (Labsystems, 
Haverhill, MA, USA) at 580 nm.
Survival percentages were determined when compared to 
untreated cells which were taken as control with a 100% survival rate.
Statistical analysis: Results were expressed as mean 
values±standard error of the mean (SEM). Mann-Whitney U test was 
used for statistical comparison between controls and other groups. 
Differences were considered significant if p < 0.05.
Results
Size and zeta potential of chitosan-LNCs 
and siRNA/chitosan-LNCs
As previously described (27), an increase in the hydro-
dynamic diameter of the chitosan-LNCs compared to the 
LNCs was observed (71 nm and 52 nm, respectively), con-
firming attachment of chitosan onto the surface of LNCs 
by the transacylation process (Table 2). The zeta potential 
of these chitosan-LNCs became positive (–6 and 24 mV 
for blank LNCs and chitosan-LNCs, respectively), allow-
ing the fixation of siRNA on their surface by  electrostatic 
Table 1: Anti-MGMT, anti-EGFR and anti-galectin-1 siRNA sequences.
siRNA Sequence
Negative control sense: 5′-GGAAAUCCCCCAACAGUGAdTdT-3′
antisense: 5′-UCACUGUUGGGGGAUUUCCTdT-3′
Anti-MGMT sense: 5′ GCUGGAGCUGUCUGGUUGUdTdT 3′
antisense: 3′ dTdTCGACCUCGACAGACCAACA 5′
Anti-EGFR sense: 5′ CACAGUGGAGCGAAUUCCUdTdT 3′
antisense: 3′ dTdTGUGUCACCUCGCUUAAGGA 5′
Anti-galectin-1 sense: 5′ GCUGCCAGAUGGAUACGAAdTdT 3′
antisense: 3′ UUCGUAUCCAUCUGGCAGCdTdT 5′
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attraction (Table 2). Regarding the siRNA/chitosan-LNCs 
complex, an increase in the hydrodynamic diameter was 
observed compared to chitosan-LNCs (±90 nm and 71 nm, 
respectively). The zeta potentials of siRNA/ chitosan-
LNCs decreased with the complexation of siRNA com-
pared to chitosan LNCs (15 mV and 24 mv, respectively) 
(Table 2) (27).
Stability of siRNA/chitosan-LNCs complexes
All complexes tested in this study were stable at 4°C and 
25°C at least for 72 h, in terms of hydrodynamic diameter, 
PDI and zeta potential. Example of the stability of anti-
EGFR/chitosan-LNCs (40 nM) is illustrated in Table 3. 
Additionally, the visual appearance of these formulations 
was identical at both temperatures. After this period, the 
Table 2: Size and zeta potential of chitosan-LNCs and siRNA/chitosan-LNCs complexes (n = 3).
Formulation siRNA 
concentration, nM
Size, nm Polydispersity 
index (PDI)
Zeta potential, mV
Blank LNCs 0 52.6±0.6 0.02 –6.4±0.4
Chitosan-LNCs 0 71.6±1.1 0.22 24.7±2.1
Chitosan-LNCs+siRNA
Anti-MGMT siRNA 5 85.0±1.2 0.26 18.6±0.7
Anti-EGFR siRNA 40 95.1±2.4 0.24 15.2±0.9
Anti-galectin-1 siRNA 40 92.9±2.6 0.28 15.9±0.6
Anti-EGFR siRNA+
Anti-galectin-1 siRNA 40+40 94.2±1.5 0.26 12.2±2.6
Anti-MGMT siRNA+
Anti-EGFR siRNA 5+40 96.0±1.6 0.26 12.6±0.9
Anti-MGMT siRNA+
Anti-galectin-1 siRNA 5+40 99.2±4.0 0.29 13.5±1.2
Anti-MGMT siRNA+
Anti-EGFR siRNA+ 5+40+40 117.5±1.3 0.28 6.2±1.7
Anti-galectin-1 siRNA+
Table 3: Stability at 4°C and 25°C of anti-EGFR/chitosan-LNCs 
 complexes (40 nM) (n = 3).
Storage 
temperature, °C
Time, h Size, nm PDI Zeta 
potential, mV
4 0 95.1±2.4 0.24 15.2±0.9
24 96.4±1.0 0.23 16.4±0.6
48 95.8±2.1 0.25 15.9±0.7
72 97.2±1.0 0.30 15.8±1.1
25 0 95.1±2.4 0.24 15.2±0.9
24 95.7±2.8 0.23 15.4±1.6
48 90.9±0.1 0.26 16.0±0.9
72 95.9±2.4 0.30 16.7±1.3
PDI of the formulations increased and exceeded 0.3 indi-
cating the heterogeneity of particles sizes.
Determination of protein expression by flow 
cytometry
Anti-MGMT siRNA
The effect of anti-MGMT siRNA carried by chitosan-LNCs 
was assessed on the MGMT expression. The treatment 
of U87MG/MGMT+ cells for 96 h, with anti-MGMT siRNA 
at the concentration of 5  nM carried by chitosan-LNCs 
resulted in a significant reduction of the target protein, 
corresponding to expression of 68.3±2.9% compared 
to the siRNA negative control (96.3±6.3%) (p < 0.05) 
(Figure 1).
Anti-galectin-1 and EGFR siRNAs
The effect of anti-galectin-1 and anti-EGFR (alone or 
in combination) siRNAs carried by chitosan-LNCs was 
assessed on their respective protein expression. The 
treatment of U87MG/MGMT- cells for 96 h with anti-galec-
tin-1 siRNA induced a significant decrease in the expres-
sion of galectin-1 compared to siRNA negative control, 
corresponded to expression of 61.5±2.1% of the target 
protein when compared with 86.8±1.7% for the siRNA 
negative control (p < 0.05) (Figure 2). In a previous study, 
we demonstrated similar results for anti-EGFR siRNA 
(27). A similar expression of galectin-1 (58.8±3.0%) was 
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Figure 1: Effect of anti-MGMT siRNA (5 nM) carried by chitosan-LNCs 
on MGMT expression in U87MG/MGMT+ after siRNA treatment for 
96 h. Data are shown as mean±SEM (n = 3) (*p < 0.05).
obtained when the U87MG/MGMT- cells were treated with 
the combination of anti-EGFR and anti-galectin-1 siRNAs 
at a concentration of 40 nM each one carried by the chi-
tosan-LNCs when compared to the siRNA negative control 
(86.8±1.7%) (p < 0.05) (Figure 3). In the same way, this 
combination induced a significant decrease of the EGFR 
expression, corresponding to expression of 54.1±1.5% 
compared to siRNA negative control (79.6±3.2%) (p < 0.05) 
(Figure 3).
Combination of anti-MGMT with galectin-1 and/or EGFR 
siRNAs
The MGMT protein expression was significantly reduced 
compared to siRNA negative control after treatment with 
the combination of anti-MGMT/anti-EGFR, anti-MGMT/
anti-galectin-1 and anti-MGMT/anti-EGFR/anti-galectin-1 
siRNAs for 96 h. The percentages of MGMT expression were 
67.8±4.6%, 64.2±2.3% and 80.3±1.7%, respectively, when 
compared to 96.3±6.3% for siRNA negative control (p < 0.05) 
(Figure 4). The percentages of EGFR expression obtained 
after treatment of the same cells with the combination of 
anti-MGMT/anti-EGFR and anti-MGMT/anti-EGFR/anti-
galectin-1 siRNAs for 96 h were 62.6±2.7% and 74.6±1.4%, 
respectively, when compared to 90.9±0.4% for siRNA nega-
tive control (p < 0.05) (Figure 4). The expression of galectin-1 
was also reduced compared to siRNA negative control after 
96 h of incubation of these cells with the combinations of 
anti-MGMT/anti-galectin-1 and anti-MGMT/anti-EGFR/
anti-galectin-1 siRNAs. The percentages of galectin-1 expres-
sion were 69.1±6.5% and 77.2±5.1%, respectively, when com-
pared to 98.6±1.8% for siRNA negative control (p < 0.05) 
(Figure 4). These results showed that the co-complexation 
of two or three siRNA did not reduce their ability to decrease 
the expression of their respective target protein.
Evaluation of the sensitivity in U87MG cells 
to TMZ after siRNA treatment
Combination of anti-galectin-1 and anti-EGFR siRNAs
The treatment of U87MG/MGMT- cells with the anti-
galectin-1 siRNA carried by chitosan- LNCs at a 
Figure 2: Effect of anti-galectin-1siRNA carried by chitosan-LNCs 
(40 nM) on the galectin-1 expression in U87MG/MGMT- after treat-
ment for 96 h. Data are shown as mean±SEM (n = 3) (*p < 0.05).
Figure 3: Effect of the combination of anti-EGFR (40 nM) and anti-
galectin-1 (40 nM) siRNAs carried by chitosan-LNCs on the EGFR and 
galectin-1 expression in U87MG/MGMT-cells. Data are shown as 
mean±SEM (n = 3) (*p < 0.05).
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Figure 4: Effect on Galectin-1, MGMT and EGFR expression after treatment of U87MG/MGMT+ cells with the combination of siRNAs (anti-
MGMT/anti-EGFR, anti-MGMT/anti-galectin-1 and anti- MGMT/anti-EGFR/anti-Galectin-1) carried by the chitosan-LNCs. siRNAs concentrations 
were 40 nM for anti-EGFR and anti-galectin-1 siRNAs and 5 nM for the anti-MGMT siRNA. Data are shown as mean±SEM (n = 3) (*p < 0.05).
concentration of 40  nM resulted in significant reduc-
tion of the percentages of living cells compared to siRNA 
negative control. Indeed, without TMZ, treatment with 
anti-galectin-1 siRNA allowed a percentage of living 
cells of 77.2±1.1% compared to 100±6.1% for siRNA 
negative control (p < 0.05). This effect was more pro-
nounced for the combination of anti-galectin-1 and anti-
EGFR siRNAs, reducing the percentage of living cells to 
61.1±1.4% when compared with 77.2±1.1% (p < 0.05) and 
100±6.1% (p < 0.05) for anti-galectin-1 siRNA alone and 
siRNA negative control (Figure 5). The effect of siRNA 
treatment was logically potentialized with the addition 
of TMZ. The percentage of living cells treated with anti-
galectin-1 siRNA and siRNA negative control was statisti-
cally different at 0.03 (p < 0.05) and 0.5 mg/mL (p < 0.05) 
of TMZ (Figure 5). For example, at 0.5 mg/mL of TMZ, the 
anti-galectin-1 siRNA allowed a percentage of living cells 
of 40.6±3.8% when compared with 74.6±8.3% for siRNA 
negative control (p < 0.05) (Figure 5). The sensitivity of 
these cells to TMZ was significantly increased when anti-
EGFR and anti-galectin-1 siRNAs were combined. At 0.5 
mg/mL of TMZ, the percentage of living cells decreased 
from 40.7±3.7% to 17.8±1.6% for anti-galectin-1 alone and 
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Figure 5: Evaluation of the sensitivity of U87MG/MGMT- cells to 
TMZ after siRNA treatment. siRNAs concentrations were 40 nM for 
anti-EGFR and anti-galectin-1 siRNAs. Data are shown as mean±SEM 
(n = 3) (*p < 0.05 and **p < 0.01).
the combination of anti-galectin-1 and EGFR siRNAs, 
respectively (p < 0.05). At 0.03 mg/mL of TMZ, the same 
conclusion can be observed (Figure 5).
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Combination of anti-MGMT with anti-galectin-1 and/or 
anti-EGFR siRNAs
The treatment of U87MG/MGMT+ cells with the anti-
MGMT siRNA alone (at the concentration of 5 nM) carried 
by chitosan-LNCs did not increase the sensitivity of these 
cells to TMZ compared to siRNA negative control. By con-
trast, when one or two siRNA (anti-galectin-1 or anti-EGFR) 
were combined to the anti-MGMT siRNA, the percentage of 
living cells (without TMZ treatment) decreased, suggesting 
the intrinsic cytotoxicity of these combinations (p < 0.05). 
No difference was observed between the three combina-
tions of siRNA (anti-MGMT/anti-EGFR; anti-MGMT/anti-
galectin-1 and anti-MGMT/anti-EGFR/anti-galectin-1). 
Logically, the cytotoxicity of theses combinations of 
siRNAs was enhanced in the presence of TMZ, showing 
the sensitization of cells to TMZ due to siRNA treatment. At 
0.5 mg/mL of TMZ, the percentage of living cells decreased 
from 55.1±1.9% to 36.0±4.1% for anti-MGMT alone and the 
combination of anti-MGMT/anti-galectin-1/anti-EGFR 
siRNAs, respectively (p < 0.05). At 0.03 mg/mL of TMZ, the 
same conclusion can be observed (Figure 6). Nevertheless, 
the combination of anti-MGMT with anti-galectin-1 or with 
anti-EGFR or with these two last ones did not present any 
statistical difference.
Discussion
In recent years, various mechanisms involved in the resist-
ance to TMZ in GB patients have been elucidated such as, 
on one side, the overexpression of MGMT and on the other 
side, the overexpression of galectin-1 and EGFR (6, 17, 31). 
Finding ways to counter the expression and functionality 
of these proteins is a real challenge to sensitize GB cells to 
the first line treatment, TMZ. The development of siRNA-
based nanotechnologies is very promising. For example, 
EGFRvIII has been targeted by Kim’s team in GB cells 
by specific siRNA transported by cyclodextrin-modified 
dendritic polyamines (DexAMs) loaded with an antican-
cer drug, Erlotinib (32). The co-delivery of anti-EGFRvIII 
siRNA and Erlotinib in GB cells was found to significantly 
inhibit cell proliferation and induce apoptosis, as com-
pared to the individual treatments. Kato et al., have used 
a mixture of anti-MGMT siRNAs carried by LipoTrust™ 
in GB cell lines, T98G and U251 which led to a significant 
increase in the sensitivity of these cell lines to TMZ com-
pared with control (33). In another study, Le Mercier et al., 
have shown that reducing galectin-1 expression in glioma 
cells by siRNA increases the anti-tumor effects of various 
chemotherapeutic agents, in particular TMZ, both in vitro 
and in vivo (17). The main limitation of these studies con-
sists is the use of vectors which are not easy to produce or 
which are not suitable for human injection. Furthermore, 
GBs are heterogeneous and highly proliferative tumors. 
Thus, targeting only one protein is not sufficient to 
increase significantly the sensitivity of the tumor to TMZ.
Many transport systems of siRNAs developed in 
recent years have high transfection efficiency and are 
produced using biocompatible and less toxic materials. 
The safety of vectors is an essential factor for clinical use 
which explains the low number of vectors used in clinical 
120
100
Control
Chitosan-LNCs
Chitosan-LNCs+anti-
galectin-1 siRNA+anti-
MGMT siRNA
Chitosan-LNCs+anti-
EGFR siRNA+anti-
MGMT siRNA
Chitosan-LNCs+anti-
EGFR siRNA+anti-
galectin-1 siRNA+anti-
MGMT siRNA
Chitosan-LNCs+anti-
galectin-1 siRNA
Chitosan-LNCs+anti-
EGFR siRNA
Chitosan-LNCs+anti-
MGMT siRNA
Chitosan-LNCs+siRNA
negative control
NS
NS
NS
NS
*
*
*
*
*
*
*
80
60
%
 o
f l
ivi
ng
 c
el
ls
40
20
0
0 0.03 0.5
Temozolomide, mg/mL
Figure 6: Evaluation of the sensitivity of U87MG/MGMT+ cells to TMZ after siRNA treatment. siRNAs concentrations were 40 nM for anti-
EGFR and anti-galectin-1 siRNAs and 5 nM for the anti-MGMT siRNA. Data are shown as mean±SEM (n = 3). (*p < 0.05).
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trials. Conventional systems such as PEI or lipofectamine® 
are widely used in vitro. However, their clinically use is 
not suitable despite their high efficiency of transfection of 
siRNA due to their toxicity profiles (34, 35).
In this work, we used chitosan-LNCs as vector for 
the delivery of siRNAs to target MGMT, EGFR and Galec-
tin-1. These particles have the advantages to be produced 
through a simple process without solvent and simply 
 purified by dialysis. This process has been previously 
adapted to produce large scale batches adapted to pre-
clinical studies (36). Chitosan was used as polymer of 
transacylation, due to its interesting physicochemical 
properties, in particular, (i) its non-toxicity compared with 
other cationic polymers such as polyethylene imine (PEI) 
(37), and (ii) its high capacity for transfection of nucleic 
acids in particular siRNAs (38, 39). The concentration of 
100 μg/mL of LNCs transacylated with 1.2 mg/mL of chi-
tosan was selected based on previous cytotoxicity assay on 
U87MG cells showing that cytotoxicity of LNCs appeared 
from 150 μg/mL of LNCs (27). Previously, we showed that 
targeting EGFR by siRNA at the concentration of 40  nM 
carried by chitosan-LNCs, reduced the expression of this 
protein and increased the sensitivity of U87MG/MGMT- 
cells to TMZ (27). Based on these encouraging results, 
we hypothesized that the targeting of MGMT, EGFR and 
galectin-1 (alone or in combination) by specifics siRNAs 
carried by chitosan-lipid nanocapsules (chitosan-LNCs) 
could enhance the sensitivity of U87MG cells to TMZ. In 
this study, we demonstrated that the treatment of U87MG 
cells by anti-MGMT siRNA associated with chitosan-LNCs 
decreased the cellular expression of MGMT but did not 
increase the cytotoxic effect of TMZ. By contrast, when 
anti-MGMT siRNA was combined with anti-galectin-1 or 
anti-EGFR siRNAs, we observed a decrease of the cellu-
lar expression of MGMT (as well as those of galectin-1 or 
EGFR) and an increase of the cytotoxic effect of TMZ.
We also demonstrated that the treatment of U87MG 
cells by anti-galectin-1 or anti-EGFR siRNAs associated 
with chitosan-LNCs decreased the cellular expression of 
galectin-1 or EGFR and increased the cytotoxic effect of 
TMZ. This effect was enhanced when anti-galectin-1 and 
anti-EGFR siRNAs were combined. Indeed, using the same 
amount of nanoparticles to avoid any additional toxicity 
related to the vector, we showed that the combination of 
these two siRNAs significantly improved toxicity of TMZ 
on U87MG/MGMT- cells compared to the effect obtained 
with the siRNA used separately.
Two different concentrations of TMZ were tested: 
0.03 and 0.5 mg/mL. These concentrations were chosen 
taking into account both the sensitivity of U87MG cells 
and the plasma concentrations described in the literature. 
The plasma concentration of TMZ was determined for 
patients with high grades gliomas. The pharmacokinet-
ics of TMZ appeared linear, with the area under the curve 
(AUC) increasing proportionally to the dose after intrave-
nous administration. For a dose of 250 mg/m2, the Cmax 
(maximum concentration) was 10 μg/mL. Measured in the 
cerebrospinal fluid, concentration was about 29% of the 
plasma concentration (40). As expected, in combination 
with siRNA treatment, the higher the TMZ concentration, 
the higher cytotoxicity. Finally, we evaluated the effect of 
the combination of the three siRNAs. The combination 
of anti-MGMT with anti-galectin-1 and anti-EGFR siRNAs 
(with the same amount of nanoparticles) did not provide 
any additional effect than the combination of anti-MGMT 
with anti-galectin-1 or with anti-EGFR siRNAs, in terms of 
cellular expression of the target proteins and cellular sen-
sitivity to TMZ. Additionnally, no difference was observed 
between the combination of anti-MGMT/anti-galectin-1 
siRNAs and the combination of anti-MGMT/anti-EGFR 
siRNAs. These results highlighted the need to combine 
strategies of the two mains signaling pathways responsi-
ble of TMZ resistance.
siRNAs could be in competition with each other and 
also with endogenous miRNAs for the RISC complex incor-
poration, this may explain the effect obtained with three 
siRNAs (41). Additionally, we observed that the zeta poten-
tial of the complex formed by the association of the three 
siRNAs with chitosan-LNCs was divided by 2 compared to 
that of the combination of two siRNAs with chitosan-LNCs. 
Several studies indicated that the intensity of the positive 
charge of the nanocarriers increases cellular uptake of the 
complexes formed with siRNAs and the inhibition effi-
ciency of the target proteins (42, 43). This could explain 
why chitosan-LNCs associated with three siRNAs failed to 
be more effective than other associations.
To combine three siRNAs, the increase of the amount 
of nanoparticles can be proposed but that may exceed 
the amount of vector-tolerated by cells. Another alter-
native consists in the increase of the particle size carry-
ing siRNAs. Additional studies are conducted to validate 
this alternative. Nevertheless, the current formulation of 
the combined anti-MGMT/anti-galectin-1 or anti-MGMT/
anti-EGFR should be further evaluated in vivo. Our vector 
has been designed for intracerebral injection, a strategy 
which offers two advantages. First, it limits the interac-
tion with plasma proteins observed with the intravenous 
route. That is why a noncovalent link between siRNA and 
LNCs seems adequate for transfection efficiency. Second, 
this approach solves the issue of crossing the blood–
brain barrier. In vivo, the formulation is better adapted 
to injection during tumor resection or can be injected in 
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the tumor by the convection enhancement delivery (CED) 
using a stereotaxic procedure.
Conclusion
In this study, we showed in vitro that (i) anti-MGMT and 
(ii) anti-EGFR or anti-galectin-1 siRNAs decreased sig-
nificantly the expression of their corresponding proteins. 
Additionally, the combination of anti-MGMT siRNA with 
either anti-EGFR or anti-galectin-1 siRNAs enhanced 
the sensitivity of U87MG cells to TMZ in comparison to 
their separately use. Interestingly, the association of the 
three siRNAs failed to be more effective than two siRNAs, 
showing that the properties of the vector have to be taken 
into account to optimize siRNA delivery and efficiency of 
their therapeutic activities.
These siRNA nanovectors due to their ease of prepa-
ration, the biocompatibility of their components and the 
possibility to encapsulate lipophilic drugs such as radio-
sensitizing agents represent a potential tool to improve 
the efficacy of the first line treatment of GB patients.
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